New Zealand markets closed

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.5798+0.0049 (+0.85%)
At close: 04:00PM EDT
0.5820 +0.00 (+0.38%)
After hours: 05:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.5749
Open0.5699
Bid0.5775 x 100
Ask0.5822 x 100
Day's range0.5699 - 0.5944
52-week range0.5030 - 5.9500
Volume321,767
Avg. volume507,601
Market cap23.862M
Beta (5Y monthly)2.42
PE ratio (TTM)N/A
EPS (TTM)-1.1200
Earnings date12 Aug 2024 - 16 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.50
  • Business Wire

    Spruce Biosciences Recognized as a Bay Area Best Place to Work

    SOUTH SAN FRANCISCO, Calif., June 06, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024.

  • Business Wire

    Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

    SOUTH SAN FRANCISCO, Calif. & MUNICH, June 04, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, and HMNC Brain Health GmbH ("HMNC"), a global precision psychiatry biopharma company, announced today a strategic collaboration to develop Spruce’s investigational product candidate, tildacerfont, a second-generation CRF

  • Business Wire

    Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024

    SOUTH SAN FRANCISCO, Calif., June 03, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine disorders with significant unmet medical need, presented results from its Phase 2 POWER study of tildacerfont, a second-generation CRF1 receptor antagonist, for the treatment of polycystic ovary syndrome (PCOS) at the 2024 Annual Meeting of the Endocrine Society (ENDO 2024).